RCS - Angle PLC - ANGLE announce Tri-Con presentation with BioView

AngleAnnouncement

25/02/2020 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200225:nRSY9730Da

RNS Number : 9730D  Angle PLC  25 February 2020

 For immediate release  25 February 2020

 

ANGLE plc ("the Company")

 

ANGLE and BioView to Present Combined Solution for Circulating Tumor Cell
Detection and Analysis at Molecular Med Tri-Con 2020 in San Francisco, 4 March
2020

 

 

ANGLE plc, (AIM:AGL OTCQX:ANPCY) a world leading liquid biopsy company, and
BioView Ltd. (TASE:BIOV), a provider of automated cell imaging and analysis
solutions, announced today that they will present results of their recent
collaboration to develop an integrated workflow for identifying clinical
biomarkers on circulating tumor cells (CTCs) at the Molecular Med Tri-Con 2020
Conference in San Francisco (Tri-Con) on March 4, 2020.

 

The collaboration combines ANGLE's Parsortix system, which enables a liquid
biopsy (a simple blood test) to be used to provide the cancer cells for
analysis in a format suitable for multiple subsequent downstream analyses, and
BioView's Duet imaging and analysis system, which provides all essential
functions required to transform resource-heavy manual CTC detection and
analysis into an automated, high-throughput, high-capacity process that is
suited to clinical practice.  Through the collaboration, ANGLE and BioView
are integrating their best-in-class technologies to create a workflow for the
isolation and characterisation of CTCs with the goal of providing clinical
insights to physicians such as the expression of HER-2 (in relation to the
drug Herceptin) and PD-L1 (in relation to immunotherapy drugs).

 

The presentation, "Combining Cell Harvesting and Imaging Technologies for CTC
Liquid Biopsy Sample-to-Answer", will be presented by Anne-Sophie
Pailhes-Jimenez, ANGLE Senior R&D Group Leader at Molecular Med Tri-Con
2020.

 

The Tri-Con Conference is a leading industry event in the personalised
medicine space. The upcoming event will focus on emerging therapeutic,
diagnostic, and technology approaches to advance precision medicine.  The
presentation will take place at 12.25 on March 4 in the Muscone South
Convention Centre, San Francisco.

 

ANGLE's Parsortix system and BioView's Duet system and associated workflows
are available for research use only as products that can be implemented in
customers' laboratories or provided as an ANGLE service with blood samples
processed and biomarker information reported.

 

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"The combination of two leading-edge technologies, ANGLE's Parsortix CTC
enrichment system and BioView's imaging and detection technology, provides a
powerful sample-to-answer workflow for the characterisation of CTCs. Such
standardised workflows will help support the development of a wide range of
clinical applications for CTCs."

 

 

For further information ANGLE:

 

 ANGLE plc                                                        +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 finnCap Ltd (NOMAD and Joint Broker)                             +44 (0)20 7220 0500

 Corporate Finance - Carl Holmes, Simon Hicks, Max Bullen-Smith

 ECM - Alice Lane, Sunila de Silva

 WG Partners (Joint Broker)                                       +44 (0) 203 705 9330

 Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee

 FTI Consulting

 Simon Conway, Ciara Martin                                       +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                                         +1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
(http://www.angleplc.com/the-parsortix-system/glossary/)

 

 

Notes for editors

 

About ANGLE plc www.angleplc.com (http://www.angleplc.com/)

 

ANGLE is a world leading liquid biopsy company with sample-to-answer
solutions. ANGLE's proven patent protected platforms include a circulating
tumor cell (CTC) harvesting technology and a downstream analysis system for
cost effective, highly multiplexed analysis of nucleic acids and proteins.

 

ANGLE's cell separation technology is called the Parsortix(®) system, and it
enables a liquid biopsy (a simple blood test) to be used to provide the cells
of interest to the user in a format suitable for multiple types of downstream
analyses. The system is based on a microfluidic device that captures cells
based on a combination of their size and compressibility.  The system is
epitope independent and can capture all types of CTCs as well as CTC clusters
in a viable form (alive).  CTCs enable the complete picture of a cancer to be
seen as being a complete cell they allow DNA, RNA and protein analysis and the
live cells harvested can be cultured.  The Parsortix technology is the
subject of 24 granted patents in Europe, the United States, China, Australia,
Canada, India, Japan and Mexico with three extensive families of patents are
being progressed worldwide.  The Parsortix system has a CE Mark in Europe for
the indicated use and FDA clearance is in process for the United States with a
400 subject clinical study and associated analytical studies in metastatic
breast cancer. ANGLE is seeking to be the first ever FDA cleared CTC
harvesting system and only the third ever FDA cleared liquid biopsy test.
ANGLE has already undertaken two separate 200 subject clinical studies under a
program designed to develop an ovarian cancer pelvic mass triage test, with
the results showing best in class accuracy (ROC-AUC) of 95.1%.  The pelvic
mass triage assay has undergone further refinement and optimisation, and is
currently in the process of a 200 patient clinical verification study.

 

ANGLE's technology for the multiplex evaluation of proteins and nucleic acids
of all types is called the HyCEAD(TM) Ziplex(®) platform and is based on a
patented flow through array technology.  It provides for low cost, highly
multiplexed, rapid and sensitive capture of targets from a wide variety of
sample types. A proprietary chemistry approach (the HyCEAD method) allows for
the capture and amplification of over 100 biomarkers simultaneously in a
single reaction. The HyCEAD Ziplex system is extremely sensitive and is ideal
for measuring gene expression and other markers directly from Parsortix
harvests and was used in the ovarian cancer pelvic mass triage test to achieve
best in class accuracy (ROC-AUC) of 95.1%.

 

ANGLE's proprietary technologies can be combined to provide automated,
sample-to-answer results in both centralised laboratory and point-of-use
cartridge formats.

 

ANGLE has established formal collaborations with world-class cancer centres
and major corporates such as Abbott, Philips and QIAGEN, and works closely
with leading CTC translational research customers.  These Key Opinion Leaders
(KOLs) are working to identify applications with medical utility (clear
benefit to patients), and to secure clinical data that demonstrates that
utility in patient studies.  The body of evidence as to the benefits of the
Parsortix system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with 28
peer-reviewed publications and numerous publicly available posters, available
on our website.

 

 

About BioView Ltd www.bioview.com (http://www.bioview.com)

 

For nearly two decades BioView has been developing, manufacturing and
marketing innovative automated cell imaging and analysis solutions, for use in
cytology, cytogenetic, pathology clinical and research laboratories. Founded
and managed by experts in the areas of medical devices, clinical and research
applications, and automated scanning systems, BioView leverages its knowledge
and expertise in the development of a dedicated scanner, designed to address
the specific challenges of CTC imaging, analysis and reporting.

 

BioView is a publicly traded company on the Tel Aviv Stock exchange, and
currently has strategic collaborations underway with international scientific
leaders and institutions. For more information about the BioView technology,
and press related issues, please contact info@bioview.co.il or visit our
website at www.bioview.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.   END  NRAGZGZZGDLGGZZ